Paul D. Burgess - Chief Business Development and Strategic Operations Officer at Cerevel Therapeutics Holdings, Inc.

Insider Transactions and Holdings

Security	Value	Price $	Transaction Date	Ownership	Underlying Class
Common Stock	$0	$41.18	Aug 1, 2024	Direct
Restricted Stock Units	$0	$41.18	Aug 1, 2024	Direct	Common Stock
Stock Option (Right to Buy)			Aug 1, 2024	Direct	Common Stock

Showing 1 to 3 of 3 entries

Sym	Class	Transaction	%	Value $	* Price $	Shares	Shares After	Date	Ownership

* An asterisk sign (*) next to the price indicates that the price is likely invalid.